Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. SELLAS Life Sciences Group, Inc.
  6. Summary
    SLS   US81642T2096

SELLAS LIFE SCIENCES GROUP, INC.

(SLS)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
3.250 USD    0.00%
01/19SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
AQ
01/05SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality
CI
01/05SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2023 01/25/2023 01/26/2023 01/27/2023 01/30/2023 Date
3.38(c) 3.45(c) 3.4(c) 3.25(c) 3.25(c) Last
156 793 163 871 145 640 183 360 154 026 Volume
-2.03% +2.07% -1.45% -4.41% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,00 M - -
Net income 2022 -39,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,55x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -30,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -3,09x
Yield 2023 -
Capitalization 66,9 M 66,9 M -
Capi. / Sales 2022 66,9x
Capi. / Sales 2023 -
Nbr of Employees 11
Free-Float 99,9%
More Financials
Company
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company's product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Its lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK) that targets the Wilms... 
Read more
More about the company
Ratings of SELLAS Life Sciences Group, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about SELLAS LIFE SCIENCES GROUP, INC.
01/19SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid..
AQ
01/05SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs,..
CI
01/05SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Hea..
AQ
2022Sellas Life Sciences Group, Inc. : Other Events, Financial Statements and Exhibits (form 8..
AQ
2022SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patien..
AQ
2022SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GF..
CI
2022SELLAS Life Sciences Says Independent Committee Recommends Galinpepimut-S Trial to Proc..
MT
2022SELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S R..
AQ
2022SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommend..
CI
2022SELLAS Life Sciences' CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo ..
AQ
2022Sellas Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in ..
CI
2022SELLAS Life Sciences' CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Sma..
AQ
2022SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study
CI
2022SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summi..
AQ
2022GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2..
AQ
More news
News in other languages on SELLAS LIFE SCIENCES GROUP, INC.
01/05SELLAS Life Sciences Group, Inc. nomme Andrew Elnatan au poste de responsable des affai..
2022SELLAS Life Sciences Group, Inc. Annonce des données positives de phase 1 avec l'inhibi..
2022SELLAS Life Sciences déclare que le comité indépendant recommande la poursuite de l'ess..
2022SELLAS Life Sciences Group, Inc. ’ ; Le comité indépendant de contrôle des données ..
2022L'inhibiteur de CDK9 GFH009 de Sellas Life Sciencesֆa été sélectionné par le Natio..
More news
Analyst Recommendations on SELLAS LIFE SCIENCES GROUP, INC.
More recommendations
ETFs positioned on SELLAS LIFE SCIENCES GROUP, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.01%-0.24%United_States
More ETFs positioned on SELLAS LIFE SCIENCES GROUP, INC.
Chart SELLAS LIFE SCIENCES GROUP, INC.
Duration : Period :
SELLAS Life Sciences Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SELLAS LIFE SCIENCES GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,25 $
Average target price 8,00 $
Spread / Average Target 146%
EPS Revisions
Managers and Directors
Angelos M. Stergiou President, Chief Executive Officer & Director
John T. Burns Chief Accounting Officer & Senior VP-Finance
Jane Wasman Independent Chairman
Dragan Cicic Senior Vice President-Clinical Development
John W. Varian Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SELLAS LIFE SCIENCES GROUP, INC.37.71%67
MODERNA, INC.5.42%69 487
LONZA GROUP AG17.81%42 878
IQVIA HOLDINGS INC.10.44%42 029
ALNYLAM PHARMACEUTICALS, INC.-2.64%27 731
SEAGEN INC.8.93%25 989